Definium Therapeutics Begins Patient Dosing in Ascend Phase 3 Depression Trial
12 maj, 15:23
09:23 AM EDT, 05/12/2026 (MT Newswires) -- Definium Therapeutics (DFTX) said Tuesday that the first patient has been dosed in Ascend, the company's second pivotal Phase 3 trial evaluating DT120 orally disintegrating tablets for major depressive disorder.
The randomized, placebo-controlled study is expected to enroll 175 participants in the US and will assess the efficacy and safety of DT120 ODT compared with placebo, the company said.
Definium said topline data from the 12-week double-blind period are expected in 2027.
Ämnen i artikeln
Definium Therapeutics Begins Patient Dosing in Ascend Phase 3 Depression Trial
12 maj, 15:23
09:23 AM EDT, 05/12/2026 (MT Newswires) -- Definium Therapeutics (DFTX) said Tuesday that the first patient has been dosed in Ascend, the company's second pivotal Phase 3 trial evaluating DT120 orally disintegrating tablets for major depressive disorder.
The randomized, placebo-controlled study is expected to enroll 175 participants in the US and will assess the efficacy and safety of DT120 ODT compared with placebo, the company said.
Definium said topline data from the 12-week double-blind period are expected in 2027.
Ämnen i artikeln
Analys
Regeringens krispaket
Analys
Regeringens krispaket
Marknadsöversikt
1 DAG %
Senast
1 mån
